Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGI-001 in Transfusion-Dependent β-Thalassemia
NCT05864170Phase 1Recruiting
- Sponsor
- Shenzhen Hemogen Therapeutic Co., Ltd.
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LentiHBBT87Q in beta thalassemia, sponsored by Shenzhen Hemogen Therapeutic Co., Ltd. Primary endpoints: Overall response rate at 24 months, Incidence and severity of AEs at 24 months and 6 more. Started May 2022; status: recruiting.
02
Drugs
LentiHBBT87Q
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05864170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864170.